Adriano Lazzarin

Research interests

Publications

• Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy

  Clinical Immunology · 2020 · https://doi.org/10.1016/j.clim.2020.108509

• Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

  Clinical Microbiology and Infection · 2020 · https://doi.org/10.1016/j.cmi.2020.10.021

• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32462-0

• Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

  The Lancet · 2017 · 10.1016/s0140-6736(17)32299-7

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  The Journal of Infectious Diseases · 2014 · https://doi.org/10.1093/infdis/jiu051

• Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

  The Journal of Infectious Diseases · 2012 · 10.1093/infdis/jis750

• Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

  The Lancet · 2011 · 10.1016/s0140-6736(11)60936-7

• Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

  Clinical Infectious Diseases · 2010 · 10.1086/656417

• Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)60918-1

• Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0708975

• Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0708978

• Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0803154

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

  The Lancet · 2007 · 10.1016/s0140-6736(07)61048-4

• The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

  AIDS · 2007 · 10.1097/qad.0b013e3280b07b33

• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

  The Lancet · 2007 · https://doi.org/10.1016/s0140-6736(07)60597-2

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

  The Lancet · 2007 · 10.1016/s0140-6736(07)60497-8

• Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

  The Lancet · 2007 · 10.1016/s0140-6736(07)60948-9

• Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

  The Lancet · 2006 · 10.1016/s0140-6736(06)69154-x

• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa040842

• Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

  JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · https://doi.org/10.1097/00126334-200408150-00003

• Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

  New England Journal of Medicine · 2003 · https://doi.org/10.1056/nejmoa035211

• Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication

  AIDS · 1998 · 10.1097/00002030-199811000-00014

• The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

  Proceedings of the National Academy of Sciences · 1997 · 10.1073/pnas.94.1.254

• Diagnosis of central nervous system complications in HIV-infected patients

  AIDS · 1997 · 10.1097/00002030-199701000-00003

• A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection

  New England Journal of Medicine · 1995 · 10.1056/nejm199508173330702

Current projects

No projects listed.